An antibody-like peptidic network for anti-angiogenesis

Kuo Zhang; Hui Zhang; Xiao-Ran Zou; Ying Hu; Da-Yong Hou; Jia-Qi Fan; Chao Yang; Zi-Ming Chen; Shi-Fang Wen; Hui Cao; Pei-Pei Yang; Lei Wang

doi:10.1016/j.biomaterials.2021.120900

An antibody-like peptidic network for anti-angiogenesis

Biomaterials. 2021 Aug:275:120900. doi: 10.1016/j.biomaterials.2021.120900. Epub 2021 May 18.

Authors

Kuo Zhang¹, Hui Zhang², Xiao-Ran Zou¹, Ying Hu³, Da-Yong Hou⁴, Jia-Qi Fan⁴, Chao Yang⁴, Zi-Ming Chen⁴, Shi-Fang Wen⁴, Hui Cao⁵, Pei-Pei Yang⁴, Lei Wang⁶

Affiliations

¹ CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), No. 11 Beiyitiao, Zhongguancun, Beijing, 100190, China; Department of Materials Physics and Chemistry, School of Materials Science and Engineering, University of Science and Technology Beijing, No. 30 Xueyuan Road, Beijing, 100083, China.
² Shanghai Jiao Tong University School of Medicine, 227 Chongqing South Road, Shanghai, 200025, China.
³ Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600, Yishan Road, Shanghai, 200233, China. Electronic address: 13046@6hospital.com.
⁴ CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), No. 11 Beiyitiao, Zhongguancun, Beijing, 100190, China.
⁵ Department of Materials Physics and Chemistry, School of Materials Science and Engineering, University of Science and Technology Beijing, No. 30 Xueyuan Road, Beijing, 100083, China. Electronic address: caohui@mater.ustb.edu.cn.
⁶ CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), No. 11 Beiyitiao, Zhongguancun, Beijing, 100190, China. Electronic address: wanglei@nanoctr.cn.

PMID: 34051670
DOI: 10.1016/j.biomaterials.2021.120900

Abstract

Different from chemical (small molecular inhibitor) and biological (monoclonal antibody) drugs, herein, based on angiogenesis-related neuropilin-1 (NRP-1), we develop a biomimetic superstructure drug, i.e. an antibody-like peptidic network (ALPN) to achieve the high-efficient treatment of choroidal neovascularization (CNV). The ALPN in nanoparticulated formulation (ALPN-NP_S) can bind NRP-1 through targeting unit and form fibrous peptidic networks trapping NRP-1 on the surface of endothelial cells (ECs), leading to anti-angiogenesis. The ALPN shows high-efficacy against angiogenesis in CNV rat model ascribed to the superstructure-enhanced binding and blockage of NRP-1. The very low dose of ALPN (0.263 μg/Kg) exhibits similar anti-angiogenesis effect comparing with monoclonal antibody bevacizumab (23.5 μg/Kg), which shows potential advantages over traditional monoclonal antibodies.

Keywords: Angiogenesis; Antibody; Biomimetic; Peptide; Self-assembly.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Angiogenesis Inhibitors / pharmacology
Angiogenesis Inhibitors / therapeutic use
Animals
Choroidal Neovascularization* / drug therapy
Endothelial Cells*
Neuropilin-1
Peptides / therapeutic use
Rats

Substances

Angiogenesis Inhibitors
Peptides
Neuropilin-1